Update on ranolazine in the management of angina (Q33831222)

29 July 2017

9 references

19 March 2019

22 March 2019

17 June 2019

17 September 2019

2 October 2019

7 November 2019

5 December 2020

27 April 2021

1 May 2021

Update on ranolazine in the management of angina (English)

1 reference

29 July 2017

9 references

19 March 2019

22 March 2019

17 June 2019

17 September 2019

2 October 2019

7 November 2019

5 December 2020

27 April 2021

1 May 2021

heterocyclic compound

1 reference

17 September 2019

1 reference

2 October 2019

1 reference

7 November 2019

1 reference

7 November 2019

1 reference

5 December 2020

1 reference

27 April 2021

1 reference

1 May 2021

sodium channel blocker

1 reference

1 May 2021

J Nicolás Codolosa

1 reference

29 July 2017

Subroto Acharjee

series ordinal

1 reference

29 July 2017

Vincent M Figueredo

series ordinal

1 reference

29 July 2017

language of work or name

English

0 references

publication date

24 June 2014

10 references

Vascular Health and Risk Management

29 July 2017

19 March 2019

22 March 2019

17 June 2019

17 September 2019

2 October 2019

7 November 2019

5 December 2020

27 April 2021

1 May 2021

10 references

29 July 2017

19 March 2019

22 March 2019

17 June 2019

17 September 2019

2 October 2019

7 November 2019

5 December 2020

27 April 2021

1 May 2021

1 reference

29 July 2017

page(s)

353-362

1 reference

Creative Commons Attribution-NonCommercial

29 July 2017

9 references

19 March 2019

22 March 2019

17 June 2019

17 September 2019

2 October 2019

7 November 2019

5 December 2020

27 April 2021

1 May 2021

on focus list of Wikimedia project

ScienceSource

0 references

cites work

Refractory atrial fibrillation effectively treated with ranolazine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4077852

Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina: results from the TERISA randomized clinical trial (Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina).

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4077852

Heart Disease and Stroke Statistics--2013 Update: A Report From the American Heart Association

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4077852

Costs and clinical outcomes associated with use of ranolazine for treatment of angina

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4077852

Ranolazine: a new approach to treating an old problem

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4077852

Effects of ranolazine on disease-specific health status and quality of life among patients with acute coronary syndromes: results from the MERLIN-TIMI 36 randomized trial

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4077852

The use of oral ranolazine to convert new or paroxysmal atrial fibrillation: a review of experience with implications for possible "pill in the pocket" approach to atrial fibrillation.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4077852

Ranolazine shortens repolarization in patients with sustained inward sodium current due to type-3 long-QT syndrome

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4077852

Long-term safety of a novel antianginal agent in patients with severe chronic stable angina: the Ranolazine Open Label Experience (ROLE).

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4077852

Inhibition of the late sodium current as a potential cardioprotective principle: effects of the late sodium current inhibitor ranolazine

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4077852

Late sodium current in the pathophysiology of cardiovascular disease: consequences of sodium-calcium overload

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4077852

Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4077852

Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4077852

Intracellular Na+ regulation in cardiac myocytes.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4077852

Regulation of myocardial carbohydrate metabolism under normal and ischaemic conditions. Potential for pharmacological interventions

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4077852

William Heberden and Some Account of a Disorder of the Breast.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4077852

RAnoLazIne for the treatment of diastolic heart failure in patients with preserved ejection fraction: the RALI-DHF proof-of-concept study

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4077852

Use of ranolazine in patients with incomplete revascularization after percutaneous coronary intervention: design and rationale of the Ranolazine for Incomplete Vessel Revascularization Post-Percutaneous Coronary Intervention (RIVER-PCI) trial

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4077852

Ranolazine reduces ventricular tachycardia burden and ICD shocks in patients with drug-refractory ICD shocks

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4077852

Electrophysiologic basis for the antiarrhythmic actions of ranolazine

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4077852

Synergistic effect of the combination of ranolazine and dronedarone to suppress atrial fibrillation.

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4077852

Efficacy of ranolazine in patients with chronic angina observations from the randomized, double-blind, placebo-controlled MERLIN-TIMI (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Segment Elevation Acute Coronary Syndromes) 36 Tr

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4077852

The effect of ranolazine on maintaining sinus rhythm in patients with resistant atrial fibrillation

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4077852

Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4077852

Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4077852

Ranolazine for the treatment of chronic angina and potential use in other cardiovascular conditions

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4077852

Clinical pharmacokinetics of ranolazine

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4077852

Effects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4077852

Can novel therapies for arrhythmias caused by spontaneous sarcoplasmic reticulum Ca2+ release be developed using mouse models?

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4077852

Studies to investigate the pharmacokinetic interactions between ranolazine and ketoconazole, diltiazem, or simvastatin during combined administration in healthy subjects

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4077852

Increased late sodium current in myocytes from a canine heart failure model and from failing human heart.

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4077852

Comparative efficacy of ranolazine versus atenolol for chronic angina pectoris

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4077852

Electrophysiologic properties and antiarrhythmic actions of a novel antianginal agent.

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4077852

Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4077852

Antagonism by ranolazine of the pro-arrhythmic effects of increasing late INa in guinea pig ventricular myocytes

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4077852

The antianginal agent trimetazidine does not exert its functional benefit via inhibition of mitochondrial long-chain 3-ketoacyl coenzyme A thiolase

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4077852

2013 ESC guidelines on the management of stable coronary artery disease

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4077852

Sodium regulation during ischemia versus reperfusion and its role in injury

29 October 2018

1 reference

12 December 2020

Gender comparison of efficacy and safety of ranolazine for chronic angina pectoris in four randomized clinical trials

1 reference

12 December 2020

Explaining the Decrease in U.S. Deaths from Coronary Disease, 1980–2000

1 reference

12 December 2020

Population trends in the incidence and outcomes of acute myocardial infarction

1 reference

12 December 2020

Cost-effectiveness of ranolazine added to standard-of-care treatment in patients with chronic stable angina pectoris

1 reference

12 December 2020

Effects of ranolazine on exercise tolerance and angina frequency in patients with severe chronic angina receiving maximally-tolerated background therapy: analysis from the Combination Assessment of Ranolazine In Stable Angina (CARISA) randomized tri

1 reference

12 December 2020

Ranolazine stimulates glucose oxidation in normoxic, ischemic, and reperfused ischemic rat hearts

1 reference

12 December 2020

Cost-utility of ranolazine for the symptomatic treatment of patients with chronic angina pectoris in Spain

1 reference

12 December 2020

Improvement in left ventricular systolic and diastolic performance during ranolazine treatment in patients with stable angina

1 reference

12 December 2020

Safety and efficacy of extended-release ranolazine in patients aged 70 years or older with chronic stable angina pectoris

1 reference

12 December 2020

Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine for Less

1 reference

12 December 2020

Ranolazine for the suppression of ventricular arrhythmia: a case series

1 reference

12 December 2020

A controlled trial with a novel anti-ischemic agent, ranolazine, in chronic stable angina pectoris that is responsive to conventional antianginal agents. Ranolazine Study Group

1 reference

12 December 2020

Comparison of effectiveness and safety of ranolazine versus amiodarone for preventing atrial fibrillation after coronary artery bypass grafting

1 reference

12 December 2020

Identifiers

DOI

10.2147/VHRM.S40477

1 reference

release_hgcithtmhnb2znurnkieggxuli

29 July 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/hgcithtmhnb2znurnkieggxuli

24 November 2022

mapped directly with Wikidata item

PMC publication ID

4077852

1 reference

29 July 2017

1 reference